geranylgeranyl pyrophosphate | 13100-78-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: geranylgeranyl pyrophosphate
• 英文别名: GGPP；geranylgeranyl diphosphate；Nerylneryl pyrophosphate；phosphono 3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraenyl hydrogen phosphate
• CAS: 13100-78-2
• 化学式: C₂₀H₃₆O₇P₂
• 分子量: 450.449
• InChiKey: OINNEUNVOZHBOX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  29
• 可旋转键数：
  14
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  113
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  geranylgeranyl pyrophosphate 在 spiroalbatene synthase from allokutzneria albata 作用下， 生成 spiroalbatene
  参考文献：
  名称：

  倍半萜和双萜的EI-MS裂解机理

  摘要：

  通过使用每个分子的全部15或20种酶促合成的13 C 1标记的同位素异构体，研究了一种细菌倍半萜烯醇和四种二萜烃的EI-MS断裂机理。特定位置的质量偏移分析表明形成每个碎片离子的碳主链部分。HR-MS / MS分析已开发出可能的破碎机制，并进一步加强了这种破碎机制。

  DOI：

  10.1002/ejoc.201800217

文献信息

• [EN] BENZAMIDE OR BENZAMINE COMPOUNDS USEFUL AS ANTICANCER AGENTS FOR THE TREATMENT OF HUMAN CANCERS<br/>[FR] COMPOSÉS BENZAMIDE OU BENZAMINE À UTILISER EN TANT QU'ANTICANCÉREUX POUR LE TRAITEMENT DE CANCERS HUMAINS
  申请人：UNIV TEXAS

  公开号：WO2017007634A1

  公开（公告）日：2017-01-12

  The described invention provides small molecule anti-cancer compounds for treating tumors that respond to cholesterol biosynthesis inhibition. The compounds selectively inhibit the cholesterol biosynthetic pathway in tumor-derived cancer cells, but do not affect normally dividing cells.

  所描述的发明提供了用于治疗对胆固醇生物合成抑制作出反应的肿瘤的小分子抗癌化合物。这些化合物选择性地抑制肿瘤来源的癌细胞中的胆固醇生物合成途径，但不影响正常分裂的细胞。
• INHIBITORS OF PRENYL-PROTEIN TRANSFERASE
  申请人：——

  公开号：US20020045759A1

  公开（公告）日：2002-04-18

  The present invention is directed to peptidomimetic compounds which inhibit prenyl-protein transferase and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting prenyl-protein transferase and the prenylation of the oncogene protein Ras.

  本发明涉及抑制异戊二烯蛋白转移酶和癌基因蛋白Ras的预尾基类似物化合物。该发明进一步涉及含有本发明化合物的化疗组合物以及用于抑制异戊二烯蛋白转移酶和癌基因蛋白Ras的预尾基化的方法。
• Method of treating cancer
  申请人：——

  公开号：US20030220241A1

  公开（公告）日：2003-11-27

  The present invention relates to methods of treating cancer using a combination of a compound which is a PSA conjugate and a compound which is a inhibitor of prenyl-protein transferase, which methods comprise administering to said mammal, either sequentially in any order or simultaneously, amounts of at least two therapeutic agents selected from a group consisting of a compound which is a PSA conjugate and a compound which is a inhibitor of prenyl-protein transferase. The invention also relates to methods of preparing such compositions.

  本发明涉及使用一种PSA共轭物和一种前脂蛋白转移酶抑制剂的组合治疗癌症的方法，该方法包括向所述哺乳动物施用来自以下组中选择的至少两种治疗剂的量，所述组包括一种PSA共轭物和一种前脂蛋白转移酶抑制剂，所述治疗剂可以顺序给药或同时给药。该发明还涉及制备这种组合物的方法。
• ISOPRENE OLIGOMER, POLYISOPRENE, PROCESSES FOR PRODUCING THESE MATERIALS, RUBBER COMPOSITION, AND PNEUMATIC TIRE
  申请人：Miyagi Yukino

  公开号：US20140171675A1

  公开（公告）日：2014-06-19

  The invention relates to an isoprene oligomer that contains a trans structural moiety and a cis structural moiety, which can be represented by the following formula (1), wherein at least 1 atom or group in the trans structural moiety is replaced by another atom or group. The invention also relates to a polyisoprene, which is biosynthesized using the isoprene oligomer and isopentenyl diphosphate. Further, this invention provides a rubber composition comprising the isoprene oligomer and/or the polyisoprene, and a pneumatic tire, including tire components (e.g., treads and sidewalls) formed from the rubber composition. wherein n represents an integer from 1 to 10; m represents an integer from 1 to 30; and Y represents a hydroxy group, a formyl group, a carboxy group, an ester group, a carbonyl group, or a group represented by the following formula (2):

  该发明涉及一种含有反式结构基团和顺式结构基团的异戊二烯寡聚物，可以用以下公式（1）表示，其中反式结构基团中至少有1个原子或基团被另一个原子或基团取代。该发明还涉及一种聚异戊二烯，它是使用异戊二烯寡聚物和异戊二烯二磷酸盐生物合成的。此外，该发明提供了一种橡胶组合物，包括异戊二烯寡聚物和/或聚异戊二烯，以及一种充气轮胎，其中轮胎组件（例如胎面和侧壁）由该橡胶组合物形成。 其中n表示1到10之间的整数；m表示1到30之间的整数；Y表示一个羟基、一个甲酰基、一个羧基、一个酯基、一个酰基或由以下公式（2）表示的基团。
• [EN] SITE-SPECIFIC RADIOFLUORINATION OF PEPTIDES WITH 8-[18F]-FLUOROOCTANOIC ACID CATALYZED BY LIPOIC ACID LIGASE<br/>[FR] RADIOFLUORATION SPÉCIFIQUE DE SITE DE PEPTIDES AVEC DE L'ACIDE 8-[18F]FLUOROOCTANOÏQUE CATALYSÉE PAR UNE ACIDE LIPOÏQUE LIGASE
  申请人：UNIV CALIFORNIA

  公开号：WO2017095806A1

  公开（公告）日：2017-06-08

  New methodologies for site-specifically radiolabeling proteins with the PET isotope [18F] are required to generate high quality radiotracers for imaging in both the preclinical and clinical settings. The enzymatic radiofluorination overcomes many of the limitations encountered to date with purely chemical approaches. The bacterial enzyme lipoic acid ligase was used to conjugate [18F]-fluorooctanoic acid to both a small peptide and a Fab antibody fragment. Labeling was site-specific and highly efficient under mild aqueous conditions using small amounts of peptide/protein (1-10 nmol). The labeled construct retained full epitope binding affinity and was stable in mouse serum. Using an optimized reaction scheme, mCi quantities of [18F]-Fab were generated, an amount sufficient for human imaging.

  用PET同位素[18F]对蛋白质进行特异性标记的新方法对于在临床前和临床环境中生成高质量放射示踪剂是必需的。酶促放氟反应克服了迄今为止纯化学方法所遇到的许多限制。细菌酶硫辛酸连接酶被用于将[18F]-氟辛酸与小肽和Fab抗体片段结合。在温和水性条件下，使用少量的肽/蛋白质（1-10 nmol），标记是特异性的且高效的。标记的构建物保留了完整的抗原结合亲和力，并在小鼠血清中稳定。使用优化的反应方案，产生了足够进行人体成像的mCi数量的[18F]-Fab。